By By Sarah Owermohle
The version that cleared committee made a big change on patent thickets. It removed a measure that allowed FTC to bring lawsuits against companies that piled on patents, but added a cap on those that can be litigated in court. Critics of the former measure said it would set FTC up for failure in court. But some argue the new version takes the teeth out of Cornyn and Blumenthal’s bill.
The senators should be commended for the progress, “but sadly some of their colleagues on the committee care more about protecting drug corporations’ ability to price gouge than affordable access to medicines for their constituents,” said Steven Knievel of Public Citizen.